

MEN/03/ZOF-CHF/001

**Comparison between zofenopril and ramipril in combination with ASA on the extent of cardiovascular risk in patients with systolic left ventricular dysfunction after acute myocardial infarction.
(SMILE IV trial)**

The study has been completed.

Results will be soon available in the “Results section”.

Sponsor: Menarini International Operations Luxembourg S.A., Laboratori Guidotti S.p.A. and Istituto Lusofarmaco d'Italia S.p.A.

Intervention: Zofenopril 30 mg bid + ASA 100 mg
Zofenopril 30 mg bid + ASA 325 mg
Ramipril 5 mg bid + ASA 100 mg
Ramipril 5 mg bid + ASA 325 mg

Condition: Systolic Left Ventricular Dysfunction after Acute Myocardial Infarction
This study is designed to demonstrate the cardiovascular benefit of the combination of Zofenopril + ASA in comparison to the combination of Ramipril + ASA on cardiovascular event rate in patients with post-MI systolic left ventricular dysfunction.

Study type & design: Randomised, double blind, controlled trial carried out in parallel groups

Main criteria for inclusion:

Acute myocardial infarction with clinical or echocardiographic evidence of systolic LV dysfunction.

Main criteria for exclusion:

Contraindications for ACE-i or ASA
SBP < 90 mmHg